A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease
Huntington's Disease / Posted 11 months ago
This study will evaluate the efficacy, safety, and biomarker effects of RO7234292 (RG6042) compared with placebo in patients with manifest Huntington’s disease (HD).
- Study start date : 01/01/2019
- Study end date : 01/03/2022
- Wales-Based Study Contact : please speak to your clinician